Owkin is an AI biotechnology company that uses federated learning, a decentralized machine learning technique, to collect and compile insights from global medical research. It trains its AI models on data from 30 academic hospitals while preserving patient privacy. Owkin’s deep learning models have developed improved predictions for cancer patient outcomes and facilitated the creation of more effective drugs for treatment. CEO Thomas Clozel, who was trained as an oncologist in Paris and New York, cofounded the company in 2016. He has raised $304 million, with a June 2022 funding round valuing the company at more than $1 billion.
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Owkin is a privately held French-American TechBio company applying multimodal AI, federated learning, biological foundation models, and agentic systems to drug discovery, clinical development, diagnostics, and biomedical research. Its strategy is increasingly centered on K Pro, an AI Scientist for biopharma decision-making, while diagnostics activities were spun out into Waiv in 2026.
Primary product
K Pro, an agentic AI Scientist and decision-support platform for biopharma research and drug development.
Founded
2016
Headquarters
New York, New York, United States — 831 Broadway, Unit 3R
Team size
201–500
Industry
Technology, Information and Internet
Sub-industry
AI-enabled biotechnology, drug discovery, clinical development, and digital pathology
Offices
Business model
Stage
Late-stage private / venture-backed growth company
Total raised
$300M
Latest round
Series B / strategic corporate financing · Jun 2022
Latest amount
$80M
Series B / strategic corporate financing
Jun 2022 · Bristol Myers Squibb
Strategic corporate investment
Nov 2021 · Sanofi
May 2020 · Bpifrance
Mar 2019 · F-Prime and Eight Roads Ventures
Leadership
Thomas Clozel
Co-founder and Chief Executive Officer
Gilles Wainrib
Co-founder
Rodrigo Barnes
Chief Technology Officer
Jean-Philippe Vert
Chief R&D Officer
Elodie Pronier
Vice President, Biomedical Discovery
Alberto Romagnoni
Head of Applied AI
Denis Dubuy
Vice President, Corporate Development
Pierre-Henri Brieau
Vice President, Legal
Marie Danielou
Finance Operations and Project Director
Public employer signals emphasize interdisciplinary work across machine learning, biology, medicine, and software engineering, with international teams and direct collaboration with pharmaceutical, hospital, and academic partners. A third-party employer profile reports an overall rating of approximately 4.2/5, with compensation, work-life, culture, and career scores around 4.2–4.4/5; this is not an official company statement.
Compensation
Public compensation data is limited. A third-party employment dataset reports approximately €64,000 annual compensation for Research Scientist roles and approximately €61,569 annual compensation for a Global Talent Project Associate role. These figures are indicative, not official salary bands.
Pricing
Enterprise SaaS and multi-year licensing for K Pro, with bespoke collaboration, data, development, and potentially milestone-based commercial terms. Public list pricing is unavailable; K Pro is offered through demos and AWS Marketplace procurement.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Approximately $50 million–$100 million annually. Sifted, as reported by TICpharma, cited 2024 revenue of approximately $86 million; a separate third-party company profile estimates $10 million, so revenue data should be treated as uncertain.
Estimated monthly visits
60.7K
Traffic estimate as of Jun 2026
Owkin reportedly planned approximately 40–50 job reductions from a workforce of about 325 through a collective voluntary redundancy program, equivalent to roughly 12%–15% of staff. The reported rationale was a strategic shift toward core AI activities and more recurring software revenue.
SourceOwkin announced the spin-out of its diagnostics business, formerly Owkin Dx, as Waiv with $33 million in financing. This reduces Owkin’s direct operating scope in diagnostics while preserving a strategic relationship with the new company.
SourceOwkin entered the therapeutic pipeline business through an exclusive global license for OKN4395 from Idorsia. This adds clinical-development and execution risk beyond Owkin’s historical software and collaboration model.
SourceOwkin · Jun 2026
Owkin announced a multi-year Sanofi collaboration and five-year K Pro license to co-develop biopharma agents for drug research and development. The agreement extends a strategic relationship that began in 2021 with a $180 million Sanofi equity investment.
Owkin · May 2026
AstraZeneca agreed to a three-year K Pro license under which Owkin will build AI agents integrated into AstraZeneca’s infrastructure and workflows, initially supporting competitive intelligence and biopharma decision-making.
Owkin · Mar 2026
Owkin spun out its diagnostics division as Waiv, backed by $33 million led by OTB Ventures and Alpha Intelligence Capital. Waiv will commercialize AI-powered precision tests while remaining strategically connected to Owkin’s patient-validation ecosystem.
Owkin · Mar 2026
Owkin integrated Consensus research search into K Pro, enabling answers grounded in more than 200 million peer-reviewed scientific articles with controls for citations, recency, and journal quality.
Owkin · Oct 2025
Owkin launched K Pro as its principal agentic AI product for biomedical research and drug development, positioning it as a recurring software and licensing business alongside existing pharmaceutical collaborations.
2 jobs at Owkin